Abstract:Background The prevalence of inflammatory bowel disease (IBD) has been on the rise in developing countries. However, the mechanism of interaction between gut microbiota and immunity, especially how probiotics regulate the imbalance of mucosal immunity in IBD, remains unclear. Hence, this study aims to explore the role of Clostridium butyricum (C. butyricum) in M2 macrophage-mediated intestinal barrier injury repairation regarding the mechanism of efferocytosis. Methods C. butyricum was treated in DSS-induced colitis mice to observe the gut barrier and the macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (A) The flow chart of the experiment). The efferocytosis-related gene expression in terms of mucosal healing was explored in colitis mice with or without clodronate liposome treatment. RNA-sequencing was used to study the mechanism of C. butyricum on macrophage efferocytosis. Results We found that C. butyricum relieved intestinal inflammation and intestinal barrier injury in colitis mice (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (B,C) The wight loss and histological images of mice). M2 macrophages and the efferocytosis-related genes were upregulated after C. butyricum treatment (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (D-I) The frequency and efferocytosis-related genes expression of macrophage). Macrophage deletion induced by clodronate liposomes prevented the role of C. butyricum on the intestinal barrier and macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (J-M) The effect of C. butyricum after macrophage clearance). RNA-sequencing revealed differentially expressed genes upregulated and downregulated (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (A) The numbers of differentially expressed genes after C. butyricum treatment). KEGG enrichment results suggested that the PPAR pathway were significantly enriched and the expression of PPAR pathway-related genes was identified (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (B,C) The result of enrichment analysis and differentially expressed genes that enriched in PPAR pathway). C. butyricum upregulated the expression of PPARδ and PPARγ, not PPARα (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (D-F) The relative expression of genes). Furthermore, PPARγ inhibitor GW9662 instead of PPARδ inhibitor GSK3787 could prevent the role of C. butyricum in inflammation suppression and macrophage efferocytosis promotion (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (G,H) The weight loss and colon length of mice). Conclusions Our findings demonstrated that C. butyricum attenuated intestinal inflammation and barrier injury by promoting M2 macrophage polarization and efferocytosis, which is partly mediated by PPARγ activation.

Butyrate Attenuates Intestinal Inflammation in Crohn’s Disease by Suppressing Pyroptosis of Intestinal Epithelial Cells Via the Cgsa-Sting-nlrp3 Axis

Butyrate attenuates intestinal inflammation in Crohn's disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis

Butyrate Prevents the Pathogenic Anemia‐Inflammation Circuit by Facilitating Macrophage Iron Export

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis

Butyrate Induces Intestinal Epithelial Cell to Express Thrombospondin 1 and Suppress Intestinal Mucosal Inflammation

Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease

Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Improve the Intestinal Epithelial Barrier to Relieve Colitis

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Butyrate Protects against Clostridium difficile Infection by Regulating Bile Acid Metabolism

Butyrate alleviates renal fibrosis in CKD by regulating NLRP3-mediated pyroptosis via the STING/NF-κB/p65 pathway

IDDF2024-ABS-0252 Clostridium Butyricum Attenuates Intestinal Barrier Injury by Promoting PPARγ-mediated Efferocytosis in Macrophages

Butyrate Ameliorated the Intestinal Barrier Dysfunction and Attenuated Acute Pancreatitis in Mice Fed with Ketogenic Diet.

Butyrate Prevents Induction of CXCL10 and Non-Canonical IRF9 Expression by Activated Human Intestinal Epithelial Cells via HDAC Inhibition

Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms.

Butyrate Protects Barrier Integrity and Suppresses Immune Activation in a Caco-2/PBMC Co-Culture Model While HDAC Inhibition Mimics Butyrate in Restoring Cytokine-Induced Barrier Disruption

Butyrate alleviates murine colitis by promoting the expansion of myeloid-derived suppressor cells

Clostridium Butyricum Alleviates Intestinal Low-Grade Inflammation In Tnbs-Induced Irritable Bowel Syndrome In Mice By Regulating Functional Status Of Lamina Propria Dendritic Cells

Butyrate Inhibits Interleukin-17 and Generates Tregs to Ameliorate Colorectal Colitis in Rats

The role of goblet cells in Crohn' s disease

Mechanism of sodium butyrate, a metabolite of gut microbiota, regulating cardiac fibroblast transdifferentiation via the NLRP3/Caspase-1 pyroptosis pathway

P163 PI(4,5)P2 alleviates colitis by inhibiting intestinal epithelial cell pyroptosis through NNMT-mediated RBP4 m6A modification